Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6131363rdf:typepubmed:Citationlld:pubmed
pubmed-article:6131363lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:6131363lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6131363lifeskim:mentionsumls-concept:C0027358lld:lifeskim
pubmed-article:6131363lifeskim:mentionsumls-concept:C0079314lld:lifeskim
pubmed-article:6131363lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6131363lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:6131363pubmed:issue20-21lld:pubmed
pubmed-article:6131363pubmed:dateCreated1983-4-21lld:pubmed
pubmed-article:6131363pubmed:abstractTextMale F344 rats were trained to discriminate between saline and d,l-ethylketazocine (EKC) in a two-choice discrete-trial avoidance task and tested with the l- and d-isomers of EKC, cyclazocine, and SKF-10,047. The effectiveness of naloxone in antagonizing the discriminative effects of d,l-EKC was also determined. Each of the l-isomers tested produced dose-related stimulus control of behavior similar to that produced by d,l-EKC. l-EKC was the most potent isomer tested, being approximately twice as potent as d,l-EKC. In contrast, d-EKC was completely devoid of activity at 300-fold higher doses. l-Cyclazocine and l-SKF-10,047 were approximately 4- and 30-fold less potent, respectively, than d,l-EKC. Although both d-cyclazocine and d-SKF-10,047 produced some drug-appropriate responding, both compounds were less potent and less efficacious than their respective l-isomers and both were significantly less efficacious than d,l-EKC. Increasing doses of naloxone (0.1 - 1.0 mg/kg) produced parallel shifts to the right in the d,l-EKC dose-effect curve. These results suggest that the discriminative effects of EKC are mediated by a stereospecific naloxone-sensitive receptor.lld:pubmed
pubmed-article:6131363pubmed:languageenglld:pubmed
pubmed-article:6131363pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:citationSubsetIMlld:pubmed
pubmed-article:6131363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6131363pubmed:statusMEDLINElld:pubmed
pubmed-article:6131363pubmed:issn0024-3205lld:pubmed
pubmed-article:6131363pubmed:authorpubmed-author:ShannonH EHElld:pubmed
pubmed-article:6131363pubmed:authorpubmed-author:HerlingSSlld:pubmed
pubmed-article:6131363pubmed:issnTypePrintlld:pubmed
pubmed-article:6131363pubmed:volume31lld:pubmed
pubmed-article:6131363pubmed:ownerNLMlld:pubmed
pubmed-article:6131363pubmed:authorsCompleteYlld:pubmed
pubmed-article:6131363pubmed:pagination2371-4lld:pubmed
pubmed-article:6131363pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:meshHeadingpubmed-meshheading:6131363-...lld:pubmed
pubmed-article:6131363pubmed:articleTitleDiscriminative effects of ethylketazocine in the rat: stereospecificity and antagonism by naloxone.lld:pubmed
pubmed-article:6131363pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6131363lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6131363lld:pubmed